[1] Grandhi MS,Lafaro KJ,Pawlik TM.Role of locoregional and systemic approaches for the treatment of patients with metastatic neuroendocrine tumors. J Gastrointest Surg,2015,19(12):2273-2282. [2] 王英伟,王叶,李杰,等. 非功能性胰腺神经内分泌肿瘤的MRI检查特征. 中华消化外科杂志,2014,13(10):768-770. [3] Kishi Y,Shimada K,Nara S,et al.Basing treatment strategy for non-functional pancreatic neuroendocrine tumors on tumor size. Ann Surg Oncol,2014,21(9):2882-2888. [4] Clewemar AP,Sundin A,Wassberg C,et al.Streptozocin and 5-FU for the treatment of pancreatic neuroendocrine tumors:efficacy,prognostic factors and toxicity. Neuroendocrinology,2015,103(3-4):345-353. [5] Xi Y,Guo R,Hu J,et al.18fluoro-2-deoxy-D-glucose retention index as a prognostic parameter in patients with pancreatic cancer. Nucl Med Communic,2014,35(11):1112-1118. [6] Chou WC,Chen JS,Hung YS,et al.Plasma chromogranin a levels predict survival and tumor response in patients with advanced gastroenteropancreatic neuroendocrine tumors. Anticancer Res,2014,34(10):5661-5669. [7] Yang M,Tian BL,Zhang Y,et al.Evaluation of the world health organization 2010 grading system in surgical outcome and prognosis of pancreatic neuroendocrine tumors. Pancreas,2014,43(7):1003-1008. [8] Lianyuan T,Dianrong X,Sadula A,et al.Surgical resection of primary tumor improves survival of pancreatic neuroendocrine tumor with liver metastases. Oncotarget,2017,8(45):79785-79792. [9] 中国胃肠胰神经内分泌肿瘤病理诊断共识专家组. 中国胃肠胰神经内分泌肿瘤病理诊断共识(2013版). 中华病理学杂志, 2013,42(10):691-694. [10] Lee L,Igarashi H,Hijioka M,et al.Sa2048 efficacy and safety of everolimus as long-term treatment in japanese patients with advanced pancreatic neuroendocrine tumors. Gastroenterology,2015,148(4S):393. [11] Haugvik SP,Kaemmerer D,Gaujoux S,et al.Pathology and surgical treatment of high-grade pancreatic neuroendocrine carcinoma:an involving landscape. Curr Oncol Rep,2016,18(5):1-7. [12] Song KB,Kim SC,Kim JH,et al.Prognostic factors in 151 patients with surgically resected non functioning pancreatic neuroendocrine tumours. Anz J Surg,2016,86(7-8):563-567. [13] 庄汉,时志鹏,胡鹏,等. HBV感染与胰腺癌发病风险关系的荟萃分析. 中华肝脏病杂志,2014,22(6):416-419. [14] 兰运彤,高正兰,袁洪胜. 不同方式十二指肠乳头括约肌切开术在经内镜逆行胰胆管造影术中的应用. 实用肝脏病杂志,2013,16(2):165-165. [15] Genc CG,Klümpen HJ,Oijen MGHV,et al.A nationwide population-based study on the survival of patients with pancreatic neuroendocrine tumors in the Netherlands. World J Surg,2017,42(17):1-8. [16] 黄超杰,张人超,牟一平,等. 腹腔镜手术治疗胰腺神经内分泌肿瘤的临床疗效. 中华消化外科杂志,2014,13(10):776-779. [17] Broder MS,Chang E,Reddy SR,et al.Treatment patterns and burden of illness in patients initiating targeted therapy or chemotherapy for pancreatic neuroendocrine tumors. Pancreas,2017,46(7):891-897. [18] 张建伟,车旭,兰忠民,等. 胰腺神经内分泌癌的外科治疗和预后. 中华肿瘤杂志,2016,38(12):925-928. [19] D'Onofrio M,Cingarlini S,Ortolani S,et al. Perfusion CT changes in liver metastases from pancreatic neuroendocrine tumors during everolimus treatment. Anticancer Res,2017,37(3):1305-1311. [20] Tsang ES,Speers C,Cheung WY,et al.Sequential treatment in patients with metastatic pancreatic neuroendocrine tumors after progression on first-line therapy. J Clin Oncol,2017,35(suppl 4):426-426. [21] 侯圣光,李永柱,张银华,等. 门冬氨酸鸟氨酸防治急性重症胰腺炎肝功能损害的疗效观察. 实用肝脏病杂志,2016,19(2):227-229. [22] Rossi S,Viera FT,Ghittoni G,et al.Radiofrequency ablation of pancreatic neuroendocrine tumors:a pilot study of feasibility, efficacy,and safety. Pancreas,2014,43(6):938-945. |